ISOFOL Share Price Performance
SEK 0.72
-0.43 (-37.23%)
Price SEK 0.72
Share Pricen/a
No recently updated narratives available.
Isofol Medical AB (publ) operates as a clinical stage biotech company. It develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. The company was incorporated in 2008 and is based in Gothenburg, Sweden.